Skip to main content
. 2021 Mar 10;13(6):8481–8496. doi: 10.18632/aging.202659

Table 2. Enriched KEGG pathways in the PCLMN.

GO term P-value Associated genes%
Hematopoietic cell lineage 2.09E-04 4.04
IL-17 signaling pathway 8.26E-06 5.32
Intestinal immune network for IgA production 9.35E-03 4.08
Chagas disease (American trypanosomiasis) 5.22E-07 5.88
African trypanosomiasis 5.42E-03 5.41
Malaria 1.42E-05 8.00
Bladder cancer 2.43E-04 7.32
Asthma 3.82E-03 6.45
Allograft rejection 5.71E-03 5.26
Primary immunodeficiency 5.71E-03 5.26
Phosphorylation of CD3 and TCR zeta chains 1.93E-03 9.09
Translocation of ZAP-70 to Immunological synapse 1.44E-03 10.53
Generation of second messenger molecules 4.59E-03 5.88
PD-1 signaling 2.11E-03 8.70
Interleukin-10 signaling 1.11E-05 8.51
FCGR3A-mediated IL10 synthesis 7.26E-03 4.65
Nucleotide-binding Oligomerization Domain (NOD) pathway 6.62E-03 4.88
Allograft Rejection 1.44E-04 4.44
Bladder Cancer 2.43E-04 7.32
IL-3 Signaling Pathway 9.35E-03 4.08
IL1 and megakaryocytes in obesity 2.50E-03 8.00
Photodynamic therapy-induced NF-kB survival signaling 5.56E-08 14.29
Lung fibrosis 8.64E-04 4.76
Hepatitis C and Hepatocellular Carcinoma 9.72E-03 4.00
T-Cell antigen Receptor pathway during Staphylococcus aureus infection 8.25E-04 4.84
Development and heterogeneity of the ILC family 4.07E-03 6.25
Platelet-mediated interactions with vascular and circulating cells 1.15E-03 11.76
LTF danger signal response pathway 2.71E-05 15.00
Cancer immunotherapy by PD-1 blockade 2.30E-03 8.33
Pathogenesis of SARS-CoV-2 Mediated by nsp9/nsp10 Complex 1.93E-03 9.09
COVID-19 AOP 9.07E-08 26.67
Cytokines and Inflammatory Response 2.91E-03 7.41
Type II interferon signaling (IFNG) 5.42E-03 5.41